Trial Profile
An evaluation of Daclatasvir and Sofosbuvir in treatment naive patients With genotype 3 chronic hepatitis C virus infection without cirrhosis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 31 Jan 2017 New trial record